Novo Nordisk/€NOVOB
1D1W1MYTD1Y5YMAX
Capital at risk
About Novo Nordisk
Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.
- Ticker
- €NOVOB
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 66,700
- Headquarters
- Bagsvaerd, Denmark
- Website
- www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
€164B
10.59
€3.50
0.35
€1.57
4.22%
Price and volume
Market cap
€164B
Beta
0.35
52-week high
€54.86
52-week low
€30.25
Average daily volume
4.3M
Dividend rate
€1.57
Financial strength
Current ratio
0.873
Quick ratio
0.642
Long term debt to equity
55.041
Total debt to equity
63.327
Dividend payout ratio (TTM)
44.64%
Interest coverage (TTM)
1,566.84%
Profitability
EBITDA (TTM)
23,232.772
Gross margin (TTM)
81.99%
Net profit margin (TTM)
35.35%
Operating margin (TTM)
48.99%
Effective tax rate (TTM)
21.72%
Revenue per employee (TTM)
€660,820
Management effectiveness
Return on assets (TTM)
18.73%
Return on equity (TTM)
59.82%
Valuation
Price to earnings (TTM)
10.586
Price to revenue (TTM)
3.738
Price to book
5.53
Price to tangible book (TTM)
12.34
Price to free cash flow (TTM)
25.769
Free cash flow yield (TTM)
3.88%
Free cash flow per share (TTM)
1.44
Dividend yield (TTM)
4.22%
Growth
Revenue change (TTM)
5.61%
Earnings per share change (TTM)
4.98%
3-year revenue growth (CAGR)
17.84%
10-year revenue growth (CAGR)
11.56%
3-year earnings per share growth (CAGR)
20.74%
10-year earnings per share growth (CAGR)
14.01%
3-year dividend per share growth (CAGR)
18.26%
10-year dividend per share growth (CAGR)
9.55%
Bulls say / Bears say
Novo Nordisk’s new Wegovy obesity pill fuelled first-quarter sales, enabling management to trim its forecasted profit and sales decline to 12% from 13% for 2026 and driving a 9.2% share rally in Copenhagen (Bloomberg).
A mid-stage trial in China of an experimental obesity drug licensed by Novo Nordisk showed participants lost up to 19.7% of body weight over 24 weeks, boosting its pipeline beyond semaglutide-based therapies (Bloomberg).
Novo Nordisk agreed to hand over its experimental Parkinson’s therapy to a Zuckerberg-backed AI startup, securing milestone payments, royalties and equity upside and exemplifying strategic pipeline diversification (Bloomberg).
Next-generation obesity treatment CagriSema fell short of Eli Lilly’s rival in a mid-stage trial, causing the OMX Copenhagen 25 Index to drop as much as 3.6% and underscoring the company’s reliance on obesity drugs (Bloomberg).
Shares plunged over 16% after investors called for a strategic pivot following disappointing CagriSema trial results, highlighting concerns over Novo Nordisk’s heavy focus on diabetes and obesity therapies (Bloomberg).
The company warned of a steep revenue drop in 2026 due to pricing pressure and looming generic competition for its blockbusters, while archrival Eli Lilly forecasts up to 27% sales growth, signaling weakening market position (Bloomberg).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Upcoming events
No upcoming events
Funds containing Novo Nordisk
AllEURGBPUSD
Fund name | Fund size | €NOVOB weighting |
|---|---|---|
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 1.32% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 1.32% |
Vanguard FTSE Developed Europe€VWCG | €3.1B | 1.00% |
Vanguard FTSE Developed Europe€VEUR | €4.8B | 1.00% |
Vanguard FTSE Developed Europe£VEUR | £4.1B | 1.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.